Principles of hemostasis in children: Models and maturation

Paediatric Anaesthesia

Volumn 21, Issue 1, 2011, Pages 3-9

  Guzzetta, Nina A ^a   Miller, Bruce E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

children; coagulation; hemostasis; maturation

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; HIGH MOLECULAR WEIGHT KININOGEN; PREKALLIKREIN; PROTEIN C; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOCYTE RECEPTOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; BLOOD FLOW; BLOOD VESSEL INJURY; CIRCULATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FIBRINOLYSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; MATURATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; THROMBOSIS; TISSUE REGENERATION; TISSUE REPAIR;

AGING; BLOOD COAGULATION FACTORS; CHILD; FACTOR VII; HEMOSTASIS; HUMANS; INFANT; INFANT, NEWBORN; MODELS, THEORETICAL; RECOMBINANT PROTEINS;

EID: 78650413284     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03410.x     Document Type: Review

References (51)

1. Brummel-Ziedins K, Orfeo T, Jenny NS, et al. Blood coagulation and fibrinolysis. In:, Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT Jr, eds. Wintrobe's Clinical Hematology, 12th edn. Philadelphia: Lippincott Williams and Wilkins, 2009: 528-529. 580-7.
2. Denis CV, Wagner DD,. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 728-739.
3. Calverley DC, Thienelt CD,. Platelet structure and function in hemostasis and thrombosis. In:, Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT Jr, eds. Wintrobe's Clinical Hematology, 12th edn. Philadelphia: Lippincott Williams and Wilkins, 2009: 499-504.
4. Jackson SP,. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-5095.
5. Stassen JM, Arnout J, Deckmyn H,. The hemostatic system. Curr Med Chem 2004; 11: 2245-2260.
6. Monroe DM, Hoffman M, Roberts HR,. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
7. Hoffman M, Monroe D,. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
8. Mann KG, Butenas S, Brummel K,. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
9. Hoffman M,. How well do we really understand coagulation? Issues Hemost Manage 2004; 1: 4-8.
10. Furie B, Furie B,. Mechanisms of thrombus formation. NEJM 2008; 359: 938-949.
11. Hoffman M, Monroe DM, Roberts HR,. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9: S61-S65.
12. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
13. Tanaka KA, Key NS, Levy JH,. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108: 1433-1446.
14. Dahlback B,. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic disease. J Intern Med 2005; 257: 209-223.
15. Huang ZF, Higuchi D, Lasky N, et al. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-951.
16. Midathada MV, Mehta P, Warner M, et al. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004; 121: 124-137.
17. Hedner U, Hedner U, Erhardtsen E,. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42: 114-124.
18. Levi M, Peters M, Büller HR,. Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.
19. Atkison PR, Jardine L, Williams S, et al. Use of recombinant factor VIIa in pediatric patients with liver failure and severe coagulopathy. Transplant Proc 2005; 37: 1091-1093.
20. Morenski JD, Tobias JD, Jimenez DF,. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. J Neurosurg 2003; 98: 611-616.
21. Guzzetta NA, Huch S, Fernandez JD, et al. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Paediatr Anaesth 2009; 19: 364-370.
22. Monroe DM, Hoffman M, Allen GA, et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-377.
23. Lisman T, De Groot PHG,. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-1139.
24. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-930.
25. O'Connell KA, Wood JJ, Wise RP,. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.
26. Szlam F, Taketomi T, Sheppard CA, et al. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg 2008; 106: 719-724.
27. Samama CM,. Prothrombin complex concentrates: a brief review. Eur J Anaethesiol 2008; 25: 784-789.
28. Fries D, Haas T, Klingler A, et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-a porcine model. Br J Anaesth 2006; 97: 460-467.
29. Dickneite G, Doerr B, Kaspereit F,. Characterization of the coagulation deficit in porcine dilutional coagulopathy and substitution with a prothrombin complex concentrate. Anesth Analg 2008; 106: 1070-1077.
30. Erber WN,. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci 2002; 27: 83-92.
31. Haas T, Fries D, Velik-Salchner C, et al. Fibrinogen in craniosynostosis surgery. Anesth Analg 2008; 106: 725-731.
32. Key NS, Negrier C,. Coagulation factor concentrates: past, present and future. Lancet 2007; 370: 439-448.
33. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
34. Sell EJ, Corrigan JJ,. Platelet counts, fibrinogen concentrations and factor V and factor VIII in healthy infants according to gestational age. J Pediatr 1973; 82: 1028-1032.
35. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy preterm infant. Blood 1988; 72: 1651-1657.
36. Kuhle S, Male C, Mitchell L,. Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin Thromb Hemost 2003; 29: 329-337.
37. Andrew M, Paes B, Johnston M,. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
38. Ling X, Delorme M, Berry L, et al. α-2-Macroglobulin remains as important as antithrombin III for thrombin regulation in cord plasma in the presence of endothelial cell surfaces. Pediatr Res 1995; 37: 373-378.
39. Schmidt B, Mitchell L, Ofosu FA, et al. α-2-Macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemost 1989; 62: 1074-1077.
40. Shah JK, Mitchell LG, Paes B, et al. Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 1992; 31: 391-395.
41. Guzzetta NA, Miller BE, Todd K, et al. Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg 2006; 103: 1131-1138.
42. Rajasekhar D, Kestin AS, Bednarek FJ, et al. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost 1994; 72: 957-963.
43. Bleyer WA, Hakami N, Shepard TH,. The development of hemostasis in the human fetus and newborn infant. J Pediatr 1971; 79: 838-853.
44. Roschitz B, Sudi K, Kostenberger M, et al. Shorter PFA-100® closure times in neonates than in adults: role of red cells, white cells, platelets and von Willebrand factor. Acta Paediatr 2001; 90: 664-670. (Pubitemid 32595871)
45. Cvirn G, Kutschera J, Wagner T, et al. Collagen/endogenous thrombin-induced platelet aggregation in cord versus adult whole blood. Neonatology 2009; 95: 187-192.
46. Teger-Nilsson AC, Ekelund H,. Fibrinogen to fibrin transformation in umbilical cord blood and purified neonatal fibrinogen. Thromb Res 1974; 5: 601-612.
47. Witt I, Hasler K,. Influence of organically bound phosphorus in fetal and adult fibrinogen on the kinetics of the interaction between thrombin and fibrinogen. Biochim Biophys Acta 1972; 271: 357-362.
48. Miller BE, Tosone SR, Guzzetta NA, et al. Fibrinogen in children undergoing cardiac surgery: is it effective? Anesth Analg 2004; 99: 1341-1346.
49. Corrigan JJ Jr, Sleeth JJ, Jeter M, et al. Newborn's fibrinolytic mechanism: components and plasmin generation. Am J Hematol 1989; 32: 273-278.
50. Parmar N, Albisetti M, Berry LR, et al. The fibrinolytic system in newborns and children. Clin Lab 2006; 52: 115-124.
51. Cvirn G, Gallistl S, Leschnik B, et al. Low tissue factor pathway inhibitor together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003; 1: 263-268.